Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.06. | Pharmala Biotech Holdings Inc: Pharmala files prospectus to issue $50M of securities | 1 | Stockwatch | ||
20.06. | PharmAla Biotech: PharmAla Files Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
04.06. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to Yale | 2 | Stockwatch | ||
03.06. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Yale University, Provides Investor Update | 1 | GlobeNewswire (USA) | ||
30.05. | Pharmala Biotech Holdings Inc: Pharmala sniffs out counterfeit nasal spray on-line | 2 | Stockwatch | ||
30.05. | PharmAla warns against fake MDMA products bearing its name | 1 | The Market Herald Canada | ||
30.05. | PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla | 149 | GlobeNewswire (Europe) | TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing... ► Artikel lesen | |
PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
15.05. | PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines | 3 | GlobeNewswire (USA) | ||
30.04. | PharmAla Biotech: PharmAla Issues Q2 Financial Statements | 1.109 | GlobeNewswire (Europe) | TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
24.03. | Pharmala Biotech Holdings Inc: Pharmala contracts third party logistics outfit in U.S. | 3 | Stockwatch | ||
24.03. | PharmAla Biotech: PharmAla Contracts with Partner to Act as US Distributor | 3 | GlobeNewswire (USA) | ||
21.03. | Pharmala Biotech Holdings Inc: Pharmala ships LaNeo MDMA to University of Washington | 3 | Stockwatch | ||
21.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to the University of Washington | 2 | GlobeNewswire (USA) | ||
10.03. | Pharmala Biotech Holdings Inc: Pharmala enters Dutch distribution deal with Duchefa | 1 | Stockwatch | ||
10.03. | PharmAla Biotech: PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands | 261 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
04.03. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to UCLA | 1 | Stockwatch | ||
03.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to UCLA for Schizophrenia Study | 1 | GlobeNewswire (USA) | ||
28.02. | Pharmala Biotech Holdings Inc: Pharmala's UT Health contract to move forward | 3 | Stockwatch | ||
27.02. | PharmAla Biotech: PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
07.02. | Pharmala Biotech Holdings Inc: Pharmala Biotech hires Azrieli for advisory services | 2 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,280 | +0,97 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 47,005 | 0,00 % | Merck schließt Übernahme von Springworks Therapeutics ab | DJ Merck schließt Übernahme von Springworks Therapeutics ab
DOW JONES--Der Pharma- und Technologiekonzern Merck hat die im April angekündigte Übernahme des US-Krebsspezialisten Springworks Therapeutics... ► Artikel lesen | |
EVOTEC | 7,250 | +0,64 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
DYNE THERAPEUTICS | 9,050 | -4,99 % | Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25... ► Artikel lesen | |
BIONTECH | 91,85 | +1,49 % | Biontech mit EILMELDUNG: Insider kaufen massenhaft Anteile - Das müssen Sie jetzt beachten! | ||
RECURSION PHARMACEUTICALS | 5,360 | +6,14 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
KYMERA THERAPEUTICS | 45,120 | +3,42 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
VOR BIOPHARMA | 1,545 | -4,04 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
MODERNA | 24,375 | +2,37 % | Moderna-Aktie gewinnt 4,07 Prozent (23,0094 €) | Im US-amerikanischen Wertpapierhandel notiert die Moderna-Aktie derzeit etwas fester. Die Aktie kostete zuletzt 26,73 US-Dollar. An der Börse liegt die Aktie von Moderna gegenwärtig im Plus. Das Papier... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,530 | +1,32 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
NUVALENT | 78,50 | +2,80 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
89BIO | 9,870 | +0,51 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
ATAI LIFE SCIENCES | 2,273 | +22,53 % | Atai and Beckley, set to merge, reveal study success for psychedelic drug | ||
ONCO-INNOVATIONS | 1,440 | -2,70 % | EQS-Media: Onco-Innovations Ltd.: Aufstrebender Hoffnungsträger in der modernen Krebsforschung: Onco-Innovations lädt zur Telefonkonferenz für Investoren ein | EQS-Media / 26.06.2025 / 11:18 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass Herr Thomas OShaughnessy,... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,910 | +5,23 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar |